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Abstract Ubiquinone (coenzyme Q10 or CoQ10)i sa
lipid-soluble component of virtually all cell membranes
and has multiple metabolic functions. Deﬁciency of
CoQ10 (MIM 607426) has been associated with ﬁve
different clinical presentations that suggest genetic
heterogeneity, which may be related to the multiple
steps in CoQ10 biosynthesis. Patients with all forms of
CoQ10 deﬁciency have shown clinical improvements
after initiating oral CoQ10 supplementation. Thus,
early diagnosis is of critical importance in the man-
agement of these patients. This year, the ﬁrst molecular
defect causing the infantile form of primary human
CoQ10 deﬁciency has been reported. The availability of
genetic testing will allow for a better understanding
of the pathogenesis of this disease and early initiation
of therapy (even presymptomatically in siblings of
patients) in this otherwise life-threatening infantile
encephalomyopathy.
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Introduction
Coenzyme Q10 (CoQ10) is the predominant human
form of endogenous ubiquinone. Synthesized in the
mitochondrial inner membrane, CoQ10 is comprised of
a ubiquinone head group attached to a tail of 10 ﬁve-
carbon isoprenoid units, that anchors the molecule to
the membranes [1]. In additions to its central role in
the mitochondrial respiratory chain as electrons carrier
from complex I and II to complex III [2], CoQ10 is now
thought to be involved in a number of cellular
functions (Table 1)[ 1]. Intracellular synthesis is the
major source of CoQ10, although a small proportion is
acquired through diet. The complexity of the biosyn-
thesis (Fig. 1) suggests that defects in different biosyn-
thetic enzymes or regulatory proteins may cause
different clinical syndromes.
Primary CoQ10 deﬁciency is an autosomal recessive
condition with a clinical spectrum that encompasses at
least ﬁve major phenotypes: (1) encephalomyopathy
characterized by the triad of recurrent myoglobinuria,
brain involvement and ragged red ﬁbers; (2) severe
infantile multisystemic disease; (3) cerebellar ataxia;
(4) Leigh syndrome with growth retardation, ataxia
and deafness; and (5) isolated myopathy [12–26].
Generalized weakness, exercise intolerance, and
recurrent myoglobinuria are the distinctive features in
the ﬁrst four patients reported with the encephalomyo-
pathic form, [12–15]; however, myoglobinuria was
absentinanotherpatient[16].Allthepatientsdescribed
sofarhaveproximalmuscleweakness[12–16]Thebrain
involvement is variable; seizures are a common ﬁnding
[12, 13], in association with cognitive impairment [12]
and cerebellar symptoms [12, 15, 16].
The second variant, described in three families,
manifests as an infantile encephalopathy with renal
involvement. Ro ¨tig and colleagues initially described
two siblings with defects of multiple quinone-depen-
dent enzymes ascribed to a deﬁciency of CoQ10 in
various tissues [17]. The patients presented with
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123retinitis pigmentosa, optic nerve atrophy, bilateral
sensorineuronal deafness, nephrotic syndrome, pro-
gressive ataxia, and cardiomyopathy. In Rahman’s
patient, hypothermia, lactic acidosis, cerebral and
cerebellar atrophy, and developmental delay were
associated with renal tubulopathy and ventricular
hypertrophy [18]. Last year, we described two siblings
who presented with nephrotic syndrome due to glom-
erulosclerosis, and the older sibling developed hypo-
tonia, psychomotor delay, seizures, stroke-like
Table 1 Functions of coenzyme Q (modiﬁed from [1])
Electron carrier in mitochondrial respiratory chain [3]
Extra-mitochondrial electron transport [4]
Antioxidant [5]
Regulation of mitochondrial permeability transition pore [6]
Regulation of physiochemical properties of membranes [7]
Modulation of the amount of b-integrins on the surface of
blood monocytes [8]
Modulator of endothelial function [9]
Oxidation of sulﬁde in yeast [10]
Introduction of disulﬁde bonds in bacteria [11]
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Fig. 1 CoQ10 biosynthetic
pathway with eight known
biosynthetic enzymes denoted
as COQ1-8. CoQ10 is
composed of a benzoquinone
and a decaprenyl side chain.
While the quinone ring is
derived from amino acids
tyrosine or phenylalanine, the
isoprenoid side chain is
produced by addition of
isopentenyl pyrophosphate
molecules to geranylgeranyl
pyrophosphate (derived from
mevalonate pathway) by
decaprenyl diphosphate
synthase. After para-
hydroxybenzoate and
decaprenyl pyrophosphate
are produced, at least seven
enzymes (encoded by COQ2-8)
catalyze condensation,
methylation, decarboxylation,
and hydroxylation reactions
to synthesize CoQ10
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Interestingly, in these infantile-onset patients, deﬁ-
ciency of CoQ10 is present not only in skeletal muscle,
but also in other tissues and cells including skin
ﬁbroblasts. In addition, two adult sisters with enceph-
alopathy, growth retardation, infantilism, ataxia,
deafness and lactic acidosis have been described by
Van Maldergam [23].
Cerebellar ataxia is the most common phenotype
associated with CoQ10 deﬁciency with 21 reported
patients [20–22, 26]. Cerebellar ataxia and cerebellar
atrophy are present in all the patients. Epilepsy is the
most common associated feature, but pyramidal signs,
mental retardation, myopathic weakness, and delayed
motor milestones are other variably associated symp-
toms and signs. Except for two adult brothers with
cerebellar ataxia and hypogonadism [22], the condition
beginsinchildhoodoradolescence. Musclemorphology
does not show ragged-red ﬁbers and lipid storage
myopathy and CoQ10 is moderately reduced in skin
ﬁbroblasts.
The clinical presentation of the variant isolated
myopathy, recently described in four patients, is
subacute onset of exercise intolerance and proximal
limb weakness at variable ages. All patients have lipid
storage and ragged-red ﬁbers in muscle, as well as
increased serum lactate and creatine kinase (CK)
[24, 25]. In all the patients with different phenotypes,
respiratory chain enzymes analyses show reduced
activities of complex I + III and II + III with normal
activities of isolated complex I and III.
In most of the reported patients, the exact site and
nature of the defects in the biosynthesis of CoQ10 have
not yet been identiﬁed. Because ubiquinone biosyn-
thesis is complex and not fully deﬁned (Fig. 1),
identiﬁcation of the molecular genetic defect is not
straightforward.
Undetectable CoQ10 and low levels of decaprenyl-
pyrophosphate, an intermediate compound in the
synthesis of the lateral chain of CoQ10 were found in
the ﬁbroblasts of the patient reported by Ro ¨tig and
colleagues suggesting a defect in the synthesis of the
decaprenyl side-chain, but they did not ﬁnd any
mutation in the cDNA of COQ1, the gene encoding
transprenyltransferase, the enzyme that synthesizes
decaprenylpyrophosphate [17].
This year, in two siblings with the infantile form of
CoQ10 deﬁciency, we reported a homozygous missense
mutation (Y297C) in the COQ2 gene, which encodes
para-hydroxybenzoate (PHB) polyprenyl transferase.
PHB-polyprenyl transferase mediates the conjugation
of the benzoquinone ring with the decaprenyl side
chain. Biochemical assays measuring incorporation of
radiolabeled PHB or decaprenyl-PP into CoQ10 in skin
ﬁbroblasts from the proband showed 23–25% of
control ﬁbroblasts activity [27] conﬁrming the defect
of CoQ10 biosynthesis.
The ﬁnding of a homozygous stop codon mutation in
the APTX gene which is known to cause ataxia-
oculomotor-aprataxia 1 (AOA1), in three siblings with
cerebellar ataxia and CoQ10 deﬁciency, supports the
hypothesis that the ataxic form is a genetically hetero-
geneous disease in which CoQ10 deﬁciency can be
secondary [28]. Aprataxin is a member of the histidine
triad superfamily and may be involved in nuclear DNA
singlestrandbreakrepair[29–31].Despitethelackofan
obviouslinkbetweenaprataxinandregulationofCoQ10
synthesis or catabolism, our ﬁndings, coupled with the
clinical improvement of patients after CoQ10 supple-
mentation, suggest that CoQ10 deﬁciency plays a path-
ogenic role in AOA1. Intriguingly, both CoQ10 and
cholesterol share a common biosynthetic pathway,
therefore, in AOA1, altered levels of these molecules
could be due to aberrant biosynthesis.
Patients with all forms of CoQ10 deﬁciency have
shown clinical improvement with oral CoQ10 supple-
mentation. The beneﬁcial effects of exogenous CoQ10
require high doses and long-term administration [32,
33]; its oral bioavailability is poor due to its extreme
hydrophobicity; therefore, only a small fraction of
orally administered CoQ10 reaches the circulatory
system, and augmentation of mitochondrial CoQ10
content is even less effective. Beneﬁcial effects of
CoQ10 supplementation are supported by in vitro
correction of biochemical and histological abnormali-
ties [12–14, 17]. However, while muscle abnormalities
improve clinically and biochemically, in general, cere-
bral symptoms are only partially ameliorated [16]. This
difference could be explained by the presence of
irreversible structural brain damage before treatment
or the poor penetration of CoQ10 across the blood-
brain barrier. Increases in plasma concentrations of
CoQ10 after oral supplementation in both humans and
animals has been well-documented, but early work
questioned whether CoQ10 accumulates in tissues [34]
and studies of 45-day-old rodents showed little or no
change in rodent brain CoQ10 concentrations after oral
administration perhaps because levels of CoQ10 are
tightly regulated in young animals or may be saturated
in membranes [34, 35]. In contrast, administration of
very high doses of CoQ10 (200 mg/kg daily) to
12–24 month-old rats produced signiﬁcant increases in
brain CoQ10 levels [36], but a more recent study of the
regional distribution of CoQ in 16 week-old rat brain
before and after 4 weeks of moderately high exogenous
dietary CoQ10 (20 mg/kg daily) supplementation
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unchanged in the cortex and in the striatum [37]. That
study also demonstrated that the cerebellum, of the 7
brain regions dissected, contains the lowest levels of
CoQ. If human brain has the same regional distribution
of CoQ10 as rat brain, the cerebellum may have the
narrowest safety margin and therefore would be the
ﬁrst tissue to suffer from a pathological shortage of
CoQ10. Moreover, to function as an antioxidant, CoQ10
must be in the reduced form but normally only 20% of
the lipid is reduced in the brain. The high proportion of
oxidized CoQ10 in the brain could be a reﬂection of the
high oxygen consumption in this tissue, causing an
increased demand of anti-oxidants [38]. Therefore,
CoQ10 deﬁciency could be another form of inherited
ataxia due to oxidative damage, as vitamin E deﬁciency.
Oxidative damage and mitochondrial dysfunction
have also been implicated in neurodegenerative dis-
eases such Parkinson disease (PD), Alzheimer disease
(AD), and Friedreich’s ataxia (FRDA) [39–41]. Pre-
clinical studies have indicated that CoQ10 can protect
the nigrostriatal dopaminergic system and high doses
(1200 mg daily) of CoQ10 for 16 months appeared to
slow progression PD [40, 42]. In 10 FRDA patients
treated for 47 months high doses of CoQ10 (400 mg
daily) with vitamin E (2100 IU daily), improved
bioenergetics in heart and skeletal muscle, improved
cardiac function by echocardiography, and, possibly
less clinical decline compared to historical controls
[43]. Larger studies are necessary to better deﬁne the
short- and long-term effects of CoQ10 as primary or
adjunctive therapy in neurodegenerative diseases.
Deﬁciency of CoQ10 has been associated with a
variety of neurological disorders that respond to oral
supplementation. We have demonstrated that CoQ10
deﬁciency can be primary due to a defect of biosyn-
thesis or secondary as in patients with APTX muta-
tions. The response of both groups of patients to oral
supplementation suggests that exogenous CoQ10 is
taken up by affected tissues and can correct biochem-
ical derangements. Further studies to deﬁne CoQ10
deﬁciency syndrome will reveal new causes, enhance
our understanding of its pathogenesis, and may provide
novel insights that may be relevant to other neurode-
generative diseases.
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